Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapyPAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 387 participantsHigh